Takehito Naito
Toyohashi, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Association of Metabolic-Associated Steatotic Liver Disease With Clinical Outcomes of Durvalumab and Tremelimumab in Advanced Hepatocellular Carcinoma Patients: A Multicenter Study.
Journal: Hepatology research : the official journal of the Japan Society of Hepatology
Published: May 27, 2025
A novel approach to evaluate the therapeutic efficacy of durvalumab and tremelimumab combination therapy in hepatocellular carcinoma.
Journal: Hepatology research : the official journal of the Japan Society of Hepatology
Published: April 18, 2025
Fever following Treatment with Atezolizumab plus Bevacizumab Predicts Liver Injury in Patients with Unresectable Hepatocellular Carcinoma: A Prospective Observational Analysis.
Journal: Liver cancer
Published: February 11, 2025
Antitumor effects and immune-mediated adverse events of durvalumab plus tremelimumab treatment for unresectable hepatocellular carcinoma.
Journal: Hepatology research : the official journal of the Japan Society of Hepatology
Published: October 04, 2024
Initial clinical experience with durvalumab plus tremelimumab in patients with unresectable hepatocellular carcinoma in real‑world practice.
Journal: Oncology letters
Published: March 01, 2024
Gastric tuberculosis in an elderly patient:a case report
Journal: Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology
Published: November 13, 2018
Diffuse large B cell lymphoma primarily presenting as acute liver failure in a surviving patient.
Journal: Journal of community hospital internal medicine perspectives
Published: November 04, 2018
Showing 1-8 of 8
Last Updated: 09/26/2026